Sanofi (EPA:SAN) has been assigned a €93.00 ($109.41) price objective by analysts at JPMorgan Chase & Co. in a report released on Thursday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 10.56% from the stock’s current price.
A number of other research firms also recently weighed in on SAN. Barclays set a €85.00 ($100.00) price objective on Sanofi and gave the company a “neutral” rating in a report on Tuesday. UBS Group set a €101.00 ($118.82) target price on Sanofi and gave the company a “buy” rating in a report on Wednesday, February 10th. Jefferies Financial Group set a €110.00 ($129.41) target price on shares of Sanofi and gave the company a “buy” rating in a report on Monday, February 8th. Credit Suisse Group set a €96.00 ($112.94) price target on Sanofi and gave the stock a “buy” rating in a report on Tuesday. Finally, The Goldman Sachs Group set a €106.00 ($124.71) price objective on Sanofi and gave the company a “buy” rating in a research note on Monday, March 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of €97.75 ($115.00).
EPA:SAN opened at €84.12 ($98.96) on Thursday. Sanofi has a one year low of €63.09 ($74.22) and a one year high of €92.97 ($109.38). The firm’s 50 day simple moving average is €80.26 and its 200 day simple moving average is €81.70.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Further Reading: How to calculate the intrinsic value of a stock
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.